Guangdong Zhongsheng Pharmaceutical (002317.SZ): Fenofibrate capsules approved to increase the 0.2g specification.

Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that the company has recently received the approval notice for the supplementary application of Fenofibrate capsules issued by the National Medical Products Administration. The supplementary application for the 0.2g specification has been approved, which is considered to have passed the consistency evaluation of generic drug quality and efficacy. It is reported that Fenofibrate has effects on lowering uric acid, inhibiting platelet aggregation, degrading lipoprotein particles in plasma, and clearing triglycerides, which can reduce serum cholesterol by 20-25% and triglycerides by 40-50%. Fenofibrate capsules are clinically used for the treatment of hypercholesterolemia (type IIa) in adults with unsatisfactory outcomes from dietary control, endogenous hypertriglyceridemia, and simple (type IV) and mixed (types IIb and III) hypertriglyceridemia. This is particularly relevant when cholesterol levels remain elevated despite dietary control or when there are other concurrent risk factors.